JP Morgan Initiates Coverage On Spyre Therapeutics with Overweight Rating, Announces Price Target of $110

JP Morgan analyst Hardik Parikh initiates coverage on Spyre Therapeutics (NASDAQ:SYRE) with a Overweight rating and announces Price Target of $110.